Impact Of Dose Modifications On Ocular Adverse Events In Phase 3 Mirasol Trial Of Mirvetuximab Soravtansine-Gynx Vs Investigator’S Choice Chemotherapy In Recurrent, Folate Receptor Alpha -Positive, Platinum-Resistant Ovarian Cancer

Published 2025 - 43rd Congress of the ESCRS

Reference: FP27.11 | Type: Free paper | DOI: 10.82333/zqb2-ac17